Shareholders of Orthovita Inc. (NSDQ: VITA), a Malvern, Pa.-based orthopedic biologics maker, are suing over a proposed $316 million merger by Stryker Corp. (NYSE:SYK ) that represents a hefty premium on VITA stock price.
Orthopedics
Welcome to MassDevice's Orthopedics Hub, your resource for the latest in orthopedic news. Stay informed about the innovations and business news shaping the ortho device industry.
🦴 Narrow your focus with these categories:
Implants | Metal-on-Metal | Spine
Here are the top orthopedic device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ The biggest stories from AAOS 2024
+ The 10 largest orthopedic device companies in the world
+ The ZimVie Tether helps kids with scoliosis — if they can get it in time
+ Could 2023 be a boom year for orthopedic devices?
+ The top orthopedic device news out of AAOS 2023
🎙️ Tune in to the Ortho Innovation Talks podcast on the DeviceTalks podcast network.
Latest Orthopedics News
Stryker launches tender offer for Orthovita
Medtronic’s Infuse bone growth product may increase male infertility
There’s more bad news for Medtronic Inc.’s (NYSE:MDT) Infuse product after a report that the bio-engineered bone growth protein can increase the risk of infertility in men, according to a study published in the June issue of The Spine Journal.
Study: Medtronic’s aortic valve replacement system improves quality of life | Research roundup
Medtronic Inc. (NYSE:MDT) announced Tuesday that its CoreValve System, designed to enable the replacement of a diseased aortic valve without open heart surgery, showed health improvements over a two-year period on patients implanted with the device. The CoreValve device won CE Mark approval in 2007.
The two-year study involved 126 patients at nine centers in Europe and Canada. The Fridley, Minn. company released the data at EuroPCR in Paris, France, an annual event that highlights the latest techniques, updates and breakthroughs in cardiovascular science.
Histogenics and ProChon Biotech merge
A pair of Bay State regenerative medicine firms, Histogenics Corp. and ProChon Biotech Ltd., merged in an all-stock deal that brings ProChon CEO Patrick O’Donnell into the Histogenics corner office.
O’Donnell told MassDevice.com that a deal has been in the works since the early part of 2011.
Stryker snaps up Orthovita for $316 million
FDA probes for data on metal-on-metal hip implants
The FDA asked Johnson & Johnson (NYSE:JNJ) and a score of other medical device makers for data on metal levels in the blood of patients implanted with metal-on-metal hip implants.
Feds accuse Wright Medical of breaking deferred prosecution deal
A day after firing its top lawyer and two other executives, Wright Medical Group (NSDQ:WMGI) said the federal prosecutor for New Jersey accused it of breaking a deferred prosecution deal Wright struck last year to settle charges that it ran an illegal kickbacks scheme.
The Arlington, Tenn.-based orthopedic device maker also said it hired a new CEO, about a month after its surprise ouster of CEO Gary Henley and CTO Frank Bono.
Smith & Nephew not jealous over Synthes/JNJ union
Officials at Smith & Nephew (NYSE:SNN) weren’t acting brides left at the altar, but they weren’t exactly tossing bouquets to the hot new couple in the orthopedic market during a conference call with investors today.
Wright Medical shakeup continues with ouster of three more executives
Just a month after a surprise shakeup at Wright Medical Group saw CEO Gary Henley abruptly resign and CTO Frank Bono fired, the company replaced three more senior executives.
The Arlington, Tenn.-based maker of orthopedic devices for the foot and ankle market said in a regulatory filing that it had accepted the resignations of senior vice president, general counsel and secretary Raymond Kolls; vice president of clinical & regulatory affairs Alicia Napoli; and senior vice president for EMEA commercial operations Cary Hagan.
Johnson & Johnson CFO: Synthes deal doesn’t mean we’re done
Johnson & Johnson (NYSE:JNJ) may have just dropped a cool $21.3 billion to acquire Synthes (SWX:SYST.VX), but it doesn’t mean the health products giant is done shopping for deals.
“Although we just did a pretty significant deal, it doesn’t preclude us from doing another one,,” CFO Dominic Caruso told an investor’s conference in Boston. “We want to be able to act.”